Calcium levofolinate

Phase 3Small molecule

Calcium levofolinate is one of 75 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Biliary Tract CancerNot yet recruiting

Pancreatic Ductal AdenocarcinomaPhase 1

Active, not recruiting

Biliary Tract CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

208 competitors in Biliary Tract Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

34 2

Imfinzi

AstraZeneca

Phase 3

26 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

32 4

Eloxatin

Teva

Phase 3

13 5

Keytruda

Merck & Co.

Phase 3

10 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

18 7

Adrucil

EElorac, Inc.

Phase 3

4 8

Herceptin

OOrganon and Co

Phase 3

4 9

Camptosar

EEastern Cooperative Oncology Group

Phase 3

3 10

Navmi

SSummit Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Not yet recruiting

Biliary Tract Cancer

NCT07582315

Clinical

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma1 trial

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Completed·UUniversity Hospital, Grenoble·Phase 1·NCT05546853·43 enrolled

Liquid Biopsy1 trial

Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB

Recruiting·AAzienda USL Reggio Emilia - IRCCS·Phase 3·NCT04776655·280 enrolled

First-line Treatment1 trial

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Unknown status·FFujian Cancer Hospital·N/A·NCT03045770·150 enrolled

Biliary Tract Cancer1 trial

A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07582315·538 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Calcium levofolinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Calcium levofolinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Calcium levofolinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fujian Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFujian Cancer Hospital

Calcium levofolinate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma1 trial

Liquid Biopsy1 trial

First-line Treatment1 trial

Biliary Tract Cancer1 trial

References

Drug Info

Quick Facts

Related News